Optimizing Precision Oncology workflows will reduce costs and make very effective treatments available to more patients, sooner!
Idealized Precision Oncology workflows:
1: Start with Liquid Biopsy early detection.
2: Proceed with precision treatments optimized for each individual's cancer's specific characteristics.
3: Continue with treatment validation and Minimal Residual Disease surveillance.
Using legacy medical methodology, we have been researching cancer as a medical condition. With the onset of precision cancer antigen targeting, and other drugs the treatment of cancer is becoming more of a bio-engineering and data engineering problem.
More efficient Lab- to-clinic processes save lives and reduce costs. Wider geographic reach increases the number of Patients treated and data gathered.
The FDA is evolving to adapt to the special requirements of Precision Oncology drug utilization.
Primary Care Provider orchestration of best-available precision Oncology treatment by specialist team consultations through HIPPA compliant data sharing using Sanguia's secure convenient remote collaboration system.
Robotic gripper adaptations, and wet lab management system integrations. Nuclear medicine pharmacy and production expertise.
Phylo phylo.bio launches with $13.5 million seed round from Andreeson. Their product: Biomni Lab, accelerates AI-native biology, allowing scientists — working across physical and computational fields — to plan, author, execute, and collaborate on complex research tasks with state-of-the-art agentic AI in a fully integrated workspace.
Drawn by high demand and Medicare reimbursement rules that reward expensive drugs and procedures, private equity firms have acquired hundreds of oncology practices nationwide, reshaping how cancer care is delivered and financed. This transformation is not merely structural—it has fundamentally altered the incentives that guide treatment decisions. https://bullmooseproject.org/posts/private-equity-in-cancer-care